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Advanced steps of tumor progression are generally character-
ized by an increased growth fraction within the neoplastic 
cell population. The presence of a relevant growth fraction is 
also related to widely accepted prognostic parameters in some 
human malignancies. Our aims were to evaluate the presence 
of a growth fraction with Ki67 monoclonal antibody 
(MoAb), and to correlate it with tumor progression and 
HLA-DR antigen expression in 88 melanocytic lesions. The 
lesions were 19 acquired melanocytic nevi, 58 primary mela-
nonl.as [divided into 26 superficial spreading melanomas 
(SSM), 24 superficial spreading melanomas with nodular 
areas (SS + NM), and five nodular melanomas (NM)] , and 11 
metastases from malignant melanomas. Ki67 MoAb stained 
16%, 19%, 71%, 100%, and 82% of nevi, SSM, SS + NM, 
T umor progression is a multistep process leading to clinically relevant events such as local invasion and metastases. Such a phenomenon is generally charac-terized by the appearance within the tumor of new-cell subpopulations expressing some selective growth 
advantage [1 ,2]. In fact, advanced tumor cell populations tend to 
increase their growth rate and escape from local growth-control 
mechanisms. Interestingly, the increase in the growth rate seems 
not to refl ect a shortening of the cell cycle time, but rather an 
increase in the growth fraction that is the proportion of neoplastic 
cell s that continue to proliferate actively instead of differentiating 
or progressing to cell death [1 l: Therefore, the evaluation of the 
growth fraction may be useful Ill understanding the evolutionary 
phase of a single tumor. Moreover, the growth fraction seems 
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Abbreviations: 
MET: metastatic melanoma 
MoAb: monoclonal an tibody 
N CM: non-classified melanoma 
NM: nodular melanoma 
SS + NM: superficial spreading melanoma with a nodular area 
SSM: superfi cial spreading melanoma 
NM, and metastases , respectively. Among primary mela-
nomas, Ki67 MoAb stained 12%, 28%, 50%, and 70% of 
tumors < 0.75, 0.75-1.49, 1.5-2.9, and :2::3 mm thick, re-
spectively. A concordant reactivity pattern for Ki67 and 
HLA-DR antigens was found in 72% of lesions (p < 
0.0001). We have shown that a representative growth frac-
tion (ie, Ki67 reactivity) is present in melanocytic lesions 
only in advanced steps of tumor progression and correlate 
with HLA-DR antigen expression. Despite the different bio-
logic values of Ki67 and HLA-DR antigens, we suggest the 
joint evaluation of both antigens as a useful marker of aggres-
sive behavior in melanoma. J Invest D ermatol 95:320-324, 
1990 
closely related to already known prognostic parameters and to rhe 
course of the disease in some malignancies, including breast cancer, 
acute leukemias, and lymphomas [3- 7]. 
Among the immunologic markers of proliferation rate, Ki6 
monoclonal antibody (MoAb), recognizing a nuclear antigen ex-
pressed in proliferating cells, is considered a reliabl e tool in evaluat-
ing the growth fraction [8-10) . Ki67 MoAb can be applied to 
frozen sections and, with th e use of currently employed immuno-
histochemical technigues, to serial sections, where both the growth 
fraction and the expression of som.e antigenic markers can be evalu. 
a ted. 
W e assessed the growth fraction using Ki67 MoAb in a group of 
melanocytic lesions in different evolutionary phases , including me-
lanocytic nevi, primary melanomas, and metastatic melanomas. Our 
aims were to evaluate the growth fraction in different steps of prO-
gression of melanocytic lesions and to correlate the presence of a 
representative growth fraction with tumor progression . In addition. 
because HLA-DR antigen expression has been demonstrated to cor-
relate with advanced stages of tumor progression in melanoma 
[2, 11 - 15], we evaluated the correlation of the growth fraction with 
the expression of HLA-DR antigens. 
MATERIALS AND METHODS 
Melanocytic Lesions Eighty-eight melanocytic lesions from 86 
patients were examined. Among the lesions were 19 melanocytic 
acquired nevi (18 common acquired nevi and one Spitz nevus), 5 
primary melanomas, and 11 melanoma metastases (five nodal and 
six cutaneous). Primary melanomas were divided into 3 groups ac-
cording to clinical and histologic evaluations [ 16}. In the first group, 
there were 26 melanomas appearing clinically as plaques and show-
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Table I. Case Definition and Immunostaining Results 
Acquired Melanocytic Nevi 
Case Histologic %Cells % Cells 
Number Type Ki67 + HLA-DR+ 
1 Compound 0 0 
2 Compound 0 0 
3 Compound 0 0 
4 Compound 0 0 
5 Compound 0 0 
6 Compound 5 0 
7 Intradermal 0 0 
8 Compound 0 0 
9 Intradermal 0 0 
10 Intradermal 0 0 
11 Junctional 0 0 
12 Intradermal 0 0 
13 Intradermal 0 0 
14 Compound 0 0 
15 Compound 0 0 
16 Compound 0 0 
17 Compound 0 0 
18 Junctional 0 0 
19 Spitz 8 0 - 10+· 
Primary Melanomas 
Case Tumor %Cells %Cells 
Number Thickness Histotypc Ki67 + HLA-DR+ 
1 0.25 SSM 0 11 -30 
2 0.30 SSM 30 11-30 
3 0.43 SSM 2 0-10+ 
4 0.50 SSM 0 0 - 10 
5 0.55 SSM 2 0-10 
6 0.60 SSM 2 0-10 
7 0.60 SSM 0 0-10 
8 0.70 SSM 0 0 -1 0 
9 0.80 SSM 2 0 - 10 
10 0.95 SSM 1 0 - 10 
11 1.08 SSM 0 0 - 10 
12 1.10 SSM 2 0-10 
13 1.20 SS+NM 11 0-10 
14 1.20 SSM 0 0 - 10 
15 1.30 SSM 0 0 - 10 
16 1.40 SS+NM 30 0-10 
17 1.50 SS+NM 1 0-10+ 
18 1.50 SS+NM 11 11-30 
19 1.65 SSM 2 0 - 10 
20 1.75 SSM 0 0 - 10 
21 1.80 SSM 0 0-10 
22 1.90 SS+NM 8 11 -30 
23 2.00 SS+NM 11 11-30 
24 2.08 SS+NM 1 0-10 
25 2.08 SSM 5 0-10 
• +.Clusters of stained tumor cel ls. 
ing radial growth phase patterns on microscopic examination (su-
perficial spreadin g melanoma (SSM)] . In the second group, there 
were 24 m elanomas appearing clinica lly as plagues plus nodule(s), 
and showin g both radial growth-phase patterns and vertical 
growth-phase patterns (superficial spreadin g melanoma with a nod-
ular area (SS + NM)] on microscopic examination. In the third 
group, there were live melanomas appearin g as nodules and with 
vertica l growth-phase patterns on microscopic examination (nodu-
lar melanomas (NM)]. 
Three additional melanomas appeared clinically as plagues plus a 
nodule but could not be evaluated according to histologic type. 
These three cases were, however, evaluated wh en tumor thickness 
was assessed. Primary melanomas were divided into fo ur groups 
according to Breslow (17]: eight tumors were less than 0.75 mm 
thick, 8 were 0.75-1.49mm thick, 14 were 1.5 -2.9 mm thick, 
and 27 were::::: 3 mm thick. The thickness of one SSM could not be 
evaluated, and therefore this case was included on ly in the evalua-
Primary Melanomas 
Case Tumor %Cells %Cells 
Number Thickness Histotype Ki67 + HLA-DR+ 
26 2.26 SSM 1 0 - 10+ 
27 2.40 SS+ NM 50 0-10 
28 2.50 SS+ NM 0 0-10 
29 2.55 SSM 5 11-30 
30 2.70 SS+NM 3 0-10 
31 3.00 SS+NM 10 0-10+ 
32 3.10 SS+NM 2 11 -30 
33 3.20 SS+ NM 3 0-10 
34 3.50 SSM 10 31-50 
35 3.50 NM 5 31-50 
36 3.50 NCM 0 0- 10 
37 3.50 SS+NM 0 0-10 
38 3.90 NCM 11 0-10 
39 3.96 SSM 1 0-10 
40 4.00 SS+NM 50 0 - 10 
41 4.00 SS+NM 20 11-30 
42 4.05 SS+NM 5 0- 10+ 
43 4.20 SSM 0 0 - 10 
44 4.25 SS+ NM 0 0- 10 
45 4.30 SS+NM 40 31-50 
46 4.30 SS+NM I 0-10+ 
47 4.40 NCM 3 0-10 
48 4.75 SSM 5 0-10+ 
49 5.20 SS+NM 70 0-10+ 
50 5.60 SS+NM 8 11 -30 
51 5.90 SS+NM 30 0-10 
52 5.90 NM 10 0-10 
53 6.00 NM 20 0- 10+ 
54 6.00 SSM 2 0- 10+ 
55 7.20 SS+NM 11 11-30 
56 7.35 NM 10 0-10 
57 15 NM 15 11 -30 
58 Not evaluable SSM 0 31-50 
Metastases 
Case %Cel ls %Cells 
Number Site Ki67 + HLA-DR + 
1 Skin 10 31-50 
2 Skin 0 0 - 10 
3 Skin 10 11-30 
4 Skin 0 0- 10 
5 Skin 15 11 -30 
6 Skin 50 0- 10 
7 Nodal 3 31-50 
8 Nodal 30 31 - 50 
9 Nodal 25 0-10 
10 Nodal 5 0-10 
11 Nodal 10 0-10 
tion by histolog ic type. Case definition is reported in T able I to-
gether with immunostaining results. 
MoAb and Staining Assay T he proliferating cells were stained 
w ith Ki67 MoAb, which reacts with a nuclear antigen expressed by 
cycling cells (Dakopatts , Copenhagen, D enmark) [8] . HLA-DR 
anti gens were identified with an anti - HLA-DR M oAb purchased 
from Becton Dickinson (Mountain View, CA, USA). An indirect 
immunoperoxidase assay was used. Acetone-fixed cryostat sections 
were incubated with MoAb for 2 h (Ki67 M oAb) or 1 h (anti -
HLA-DR MoAb); they were later incubated with goat bio tinylated 
Fab-antimouse serum (Amersham, Buckingamshire, UK) and then 
with streptavidin-biotin-peroxidase complex (Amersham). The 
peroxidase reaction was performed with 3-amino-9-ethyl carbazole 
and H 20 2 in acetate buffer. Counterstaining was done with Mayer's 
hematoxylin. N ega tive controls were run in parallel. The positive 
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reaction of Ki67 MoAb with normal epidermis in the same section 
of each lesion served as an internal control. 
Evaluation T he percentage of stained cells in each section was 
evaluated by two independent observers. In most cases, the two 
observers agreed; when differences were present, they were resolved 
by consensus. The growth fraction was assessed as the percentage of 
cells reacting with Ki67 MoAb in the whole section. Sections were 
indicated as positive when at least 3% of tumor cells were stained 
with Ki67 MoAb (such lesions were considered to have a represent-
ative growth fraction), and when at least 11% or clusters of tumor 
cells were stained with anti-HLA-DR MoAb. HLA-DR + melano-
cytic cells were carefully differentiated from HLA-DR + cells be-
longing to the reactive infiltrate with use of OKT11 (Ortho Diag-
nostic System, Raritan, NJ) and anti-LCA (Dako) MoAb on serial 
sections. 
Statistical Analysis The X2 test was used. 
RESULTS 
The histopathologic features and results of immunostaining for 
Ki67 and HLA-DR antigens of 88 melanocytic lesions are listed in 
Table I, and representative staining in two cases is illustrated in Figs 
1 and 2. 
Figures 3 and 4 show the percentage of Ki67-stained cells per 
lesion. Melanocytic lesions are divided according to histopathologic 
features (Fig 3) and primary melanomas according to tumor thick-
ness (Fig 4). When a vertical growth pattern is present in primary 
melanomas, higher growth fractions are seen (Fig 3); similar values 
are observed among metastases. Although the highest values of 
growth fraction are observed in thick primary melanomas, a corre-
lation between growth fraction and tumor thickness was not found 
(Fig 4). Figures 5 and 6 show the number of K.i67 and HLA-DR-
positive lesions classified according to the histopathologic features 
of melanocytic lesions or to tumor thickness of primary melanomas, 
respectively. Figure 5 shows that 16%, 19%, 71%, 100%, and 82% 
of nevi, SSM, SS + NM, NM, and metastases, respectively, were 
Figure 1. A superficial spreading melanoma with a nodular area. A, stain-
ing of melanoma cells with Ki67 MoAb; B, staining of melanoma cells in the 
same area with anti-HLA-DR MoAb. Bar, 100 Jlrn. 
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Figure 2. A cutaneous melanoma metastasis. A, melanoma cells stained 
with Ki67 MoAb; B, reactive infiltrating cells are stained with anti HLA-DR 
MoAb, whereas melanoma cells are not stained. Bar, 100 Jlm. 
positively stained by Ki67 MoAb (X2 = 34.8;y < 0.000001). Fig-
ure 6 shows that 12%, 28%, 50%, and 70% of primary melanomas 
< 0.75, 0.75-1.49, 1.5-2.9, and 2:3 mm thick, respective! •, 
reacted positively with Ki67 MoAb. Due to the fact that the X2 test 
was not applicable because the numbers were too small , we tested 
melanomas less than 3 mm thick vs melanomas more than 3 rum 
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Figure 3. Growth fraction in melanocytic lesions expressed as percen~ 
of Ki67-stained cells per each lesion. ~ 
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Figure 4. Growth fraction in primary melanomas expressed as percentage 
ofKi67 stained ce lls per each lesion. 
rbick only. {X2 = 7.8; p = 0.0049.) HLA-DR reactivity was found 
in S% , 35%,54%,60%, and 45% of nevi, SSM, SS + NM, NM, and 
metastases, respectively (X2 = 7.64; p = 0.007) (Fig 5), and in 37%, 
0%, 47%, and 56% of primary melanomas < 0.75, 0.75 - 1.49, 1.5 -
2.9, > 3 mm thick, respectively {x2 = 8.98; p = 0.029) {Fig 6) . A 
concordant reactivity pattern for Ki67 and HLA-DR antigens was 
found in 72% of lesions. Both antigens were expressed in 26% of 
lesions and neither of them was present in 45% of lesions (Table II) . 
The degree of concordance was statistical ly significant {p < 
0.0001). 
DISCUSSION 
We have demonstrated th at the increased frequency of a representa-
tive growth fraction identified by Ki67 MoAb was associated with 
rumor progression in melanocytic lesions. In fact, a representative 
growth fraction was observed among 19 nevi in onl y two lesions, 
one of them a Spitz nevus. Among primary melanomas, positive 
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Figure 5. Pos itive and negative staining of melanocytic les ions for Ki67-
(~lid sq uares) and HLA-DR- (opw circles) antigen expression. 
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Figure 6. Positive and negative srai r~in g of p~imary melanomas for Ki67-
(sol id squares) and HLA-DR - (opeu crrcles) antrgen expressiOn. 
Ki67 sta ini ng was seen with increasing frequency according to in-
creasing tumor thickness and accord ing. to histotype. Amon g 11 
metastases, posit ive staining was fo und 111 all but two leswns. In 
addition, we observed a correlation betwee n Ki67 antigen expres-
sion and HLA-DR antigen expression, which is considered a pro-
gression marker [2,1 1 - 15]. Ki67 score was found to be an objeCtive 
indicator of biologic behavior in breast ca ncer [5,18 - 20] and to be 
of some prognostic significa nce in non-Hodgkin 's lymphoma [7,9]. 
In mclanocytic lesions, Ki67 sta ining has been correlated With the 
malignant potential of conge nital nevi [21] and with histopatholog-
ical ly assessed prognostic variables in melanoma [22,23] . Prevwus 
studies of tumor cell kinetics, performed mamly on metasta tiC mela-
noma, ac tuall y showed that stage II patients w ith tumors w1th a 
hi gh labeling index had a lower probability for two years of survival 
[24]. Moreover, the S-fraction de termined by flow cytometry was 
proved to be an important indicator of overall surv1val [25]. At 
present, we are not able to assess the value of Ki67 sc_ore as a prog-
nostic facto r in melanoma because the follow-up penod of our pa-
tients has not been long enough. In our study, we found no si~~ifi­
ca nt association between Ki67 antigen expression and cluuca l 
parameters such as age, sex of patients, and site of the primary 
melanoma, bur we found a clear corre lation ofKi67 antigen expres-
sion and tumor thickness , wh ich is a proved indicator of a poor 
prognosis. It was, however, recently pointed out, in a la:ge series of 
patients, th at rumor thickn ess is not a reliable prognostic factor for 
thin primary melanoma (1e, thmner th an 1.5 mm) [26]. It would be 
interesting to establish, by mea ns of an adequate fo llow-up, whether 
Ki67 score is of prognostic significa nce for thm melanomas. 
At prese nt , 12 of 58 stage I patients have ha? a relaps_e; 6 of 12 had 
both Ki67 and HLA-DR ann ge ns expressed 111 the pnmary tumor, 
nine of 12 expressed Ki-67 antigen, and three of 12 expressed HLA-
DR antigen. Thus 11 of 12 expressed at least one of the two ann -
gens. In add ition, four of five patients who have d 1ed had a pnmary 
melanoma with a high percentage of Kl-67 -stamed tumor cells. It 
is noteworthy that one of these patients had the only thm pnmary 
melanoma of the present series (0 .3 mm, II level, with regression) , 
with a high percentage ofKi~67 - stained tumor c_e lls {30%). There-
fore, despite the differenr bro log1c values of Kl67 and HLA-DR 
anti gens, we suggest rheJ0111t evaluation of both antigens as a useful 
marker of aggressive behaviOr 1n melanoma. 
Table II. Concordance of Ki67 and HLA-DR Antigen 
Express ion in 88 Melanocytic Lesions 
HLA-DR + 
HLA-DR -
Total 
Ki67+ 
23 
17 
40 
Ki67-
8 
40 
48 
31 
57 
88 
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